New ownership structure positions TrueBlue to deliver greater speed, scale, and commercial reach for sponsors and CROs via hyperCORE’s integrated operations and marketing platform.

TrueBlue Clinical Research has recently transitioned to private ownership, unlocking greater agility to invest in site operations, patient access, and business development. As part of this growth plan, TrueBlue is re-engaging hyperCORE International as a strategic partner by leveraging hyperCORE’s coordinated marketing, brand visibility, and sponsor/CRO engagement channels alongside its harmonized operational frameworks. The combined focus is simple: accelerate study start-up, increase enrollment velocity, and deliver consistently high-quality execution across priority therapeutic areas.

Jeffrey Smyth, President and Executive Director of TrueBlue Clinical Research, said, “Moving to private ownership gives us the freedom to double down on what sponsors and CROs value most—speed, reliability, and scientific rigor. Partnering with hyperCORE is a strategic growth initiative that expands our commercial reach and brings new scale to our best-in-class operations.”

He added, “hyperCORE’s alliance of independent, high-performing partner site networks offers both operational synergies and a strong go-to-market platform. That combination aligns perfectly with TrueBlue’s mission to deliver scalable, efficient, and patient-centric trial solutions.”

With clinical operations in Tampa, Florida, TrueBlue conducts multi-specialty Phase I–IV trials supported by a certified, experienced research team and robust infrastructure that includes CLIA/PPM licensure, local lab partnerships, centrifugation, cold-chain capacity, and safety equipment for higher-acuity procedures. Therapeutic strengths span dermatology, allergy/asthma, immunology, internal medicine, infectious disease, neurology, mental health, ophthalmology, vaccines, and device studies, with demonstrated performance across high-enrolling programs. TrueBlue’s leadership has also modernized site operations to support sustainable growth, deploying integrated eClinical platforms to streamline finance, documents, and study workflows—improving data integrity and audit readiness while enabling faster execution.

What This Means for Sponsors and CROs

• Commercial lift + operational discipline: hyperCORE’s robust business development team amplifies sponsor engagement and TrueBlue’s visibility while harmonized frameworks support faster start-up and consistent delivery.
• Scalable enrollment: expanded reach across therapeutic areas with quality-managed workflows and on-site expertise for higher-acuity procedures.
• Single-contact simplicity: access to broader network resources and standardized processes without sacrificing local bandwidth and staff burden.